Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The primary objective of the proposed investigation is to evaluate the efficacy of the Provent device in a sample of OSA patients who have either refused or been non-adherent with PAP treatment. Both initial efficacy (evaluated after approximately one week with Provent) and efficacy after approximately 5 weeks in patients who demonstrate initial efficacy will be assessed. A secondary objective is to assess adherence with Provent treatment during the 5-week evaluation period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Current signs and symptoms consistent with a diagnosis of OSA in the opinion of the study physician
Rejection of PAP treatment or minimally adherent with PAP treatment
Use of the Provent device for a specified amount of time each night during three consecutive nights of the trial period
AHI > 15, or AHI > 10 with evidence of CMS-recognized symptoms or co- morbidities, on screening/baseline PSG
Investigator believes that subject can benefit from OSA treatment
Subject understands and is willing and able to comply with study requirements
Use of any device that interferes with nasal or oral breathing
Persistent blockage of one or both nostrils which prevents airflow in one or both nostrils
Any chronic sores or lesions on the inside or outside of the nose
Chronic use of nasal decongestants other than nasal steroids
History of allergic reaction to acrylic-based adhesives (such as those found in BAND-AIDS®)
Current acute upper respiratory (including nasal, sinus, or middle ear) inflammation or infection or perforation of the tympanic membrane (may be re-considered for participation after the acute episode resolves)
History of frequent and/or poorly treated severe nasal allergies or sinusitis which may interfere with the ability to use Provent
Narcolepsy, idiopathic hypersomnolence, chronic insomnia, restless legs syndrome, REM sleep behavior disorder or any other diagnosed or suspected sleep disorder other than OSA that could affect the likelihood of apneas/hypopneas during a PSG.
Periodic limb movement arousal index (PLMAI) > 10 on the screening/baseline PSG.
Current use of diurnal or nocturnal supplemental oxygen
Currently working night or rotating shifts
Consumption of > 10 caffeinated beverages per day (approximately 1000 mg per day)
History of severe cardiovascular disease, including New York Heart Association Class III or IV heart failure, coronary artery disease with angina or myocardial infarction in the past 6 months, stroke in the past 6 months
History of cardiac rhythm disturbance (defined as a 5-beat run of sustained ventricular tachycardia or bradycardia if < 30 beats per min for a 10-second run or previously undiagnosed and untreated atrial fibrillation or Mobitz II or third-degree heart block)
Current psychiatric disorder with psychotic features.